Timothy Coughlin - 11 May 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Reporting relationship: Director
Issuer ticker: ATYR
Reported as of: 11 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2026, 16:17:25 UTC
Prior SEC filing: 04 Nov 2025
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy E. Denyes, as Attorney-in-Fact

Key filing fact

Timothy Coughlin filed Form 4 for aTYR PHARMA INC (ATYR) on 13 May 2026.

Key facts

This page summarizes Timothy Coughlin's Form 4 filing for aTYR PHARMA INC (ATYR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 May 2026, 16:17.

Change

Previous filing in this sequence was filed on 04 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001376043 Primary reporting owner

Coughlin Timothy

Relationship: Director
Address: C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO
Signature: /s/ Nancy E. Denyes, as Attorney-in-Fact
Signature date: 13 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATYR transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.9500
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.